Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend

Editas Medicine

09/03/2026 11:15

Overview

Gene editing firm's Q4 net loss beat analyst estimates

Collaboration and R&D revenue decreased due to prior milestone revenue recognition

Company maintains strong cash position with runway into Q3 2027

Outlook

Editas plans IND/CTA submission for EDIT-401 by mid-2026

Result Drivers

LOWER R&D EXPENSE: Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024.

Company press release: ID:nGNX8VPqVz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration and other research and development revenue
$24.70 mln
Q4 EPS
-$0.06
Q4 Net Income
Beat
-$5.62 mln
-$24.29 mln (9 Analysts)
Q4 Basic EPS
-$0.06
Q4 Operating Expenses
$32.50 mln
Q4 Operating Income
-$7.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 100% above its March 6 closing price of $2.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)